Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)
12.29
0.00 (0.00%)
At close: Apr 23, 2025, 2:57 PM CST
SHE:301301 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 5,397 | 4,515 | 3,574 | 3,055 | 3,366 | Upgrade
|
Other Revenue | 361.61 | 308.58 | 246.72 | 177.08 | 283.45 | Upgrade
|
Revenue | 5,758 | 4,823 | 3,821 | 3,232 | 3,649 | Upgrade
|
Revenue Growth (YoY) | 19.38% | 26.24% | 18.21% | -11.44% | 16.10% | Upgrade
|
Cost of Revenue | 3,680 | 3,343 | 2,890 | 2,637 | 3,007 | Upgrade
|
Gross Profit | 2,078 | 1,480 | 930.89 | 595.07 | 641.97 | Upgrade
|
Selling, General & Admin | 190.87 | 165.7 | 155.54 | 130.22 | 122.59 | Upgrade
|
Research & Development | 77.73 | 55.26 | 35.38 | 32.95 | 25.05 | Upgrade
|
Other Operating Expenses | 79.51 | 66.52 | 54.94 | 36.7 | 36.14 | Upgrade
|
Operating Expenses | 341.43 | 293.98 | 260.12 | 198.27 | 184.53 | Upgrade
|
Operating Income | 1,737 | 1,186 | 670.77 | 396.8 | 457.44 | Upgrade
|
Interest Expense | -61.91 | -87.78 | -142.34 | -176.88 | -173.66 | Upgrade
|
Interest & Investment Income | 7.38 | 16.18 | 5.21 | 9.2 | 3.11 | Upgrade
|
Currency Exchange Gain (Loss) | 6.69 | 12.18 | 14.71 | -5.37 | -8.35 | Upgrade
|
Other Non Operating Income (Expenses) | -5.83 | -3.74 | -0.64 | -0.95 | -1.48 | Upgrade
|
EBT Excluding Unusual Items | 1,683 | 1,123 | 547.7 | 222.8 | 277.07 | Upgrade
|
Gain (Loss) on Sale of Investments | -9.16 | -14.73 | -8.96 | 0.55 | 0.42 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 1.34 | - | 0.26 | - | Upgrade
|
Asset Writedown | - | - | - | -5.79 | -1.41 | Upgrade
|
Other Unusual Items | 1.22 | 7.97 | -51.11 | -83.74 | - | Upgrade
|
Pretax Income | 1,675 | 1,118 | 487.63 | 134.08 | 276.07 | Upgrade
|
Income Tax Expense | 274.74 | 177.15 | 76.11 | 22.73 | 47.07 | Upgrade
|
Earnings From Continuing Operations | 1,400 | 940.56 | 411.52 | 111.35 | 229 | Upgrade
|
Minority Interest in Earnings | -0.03 | -0 | 0 | -0 | -0 | Upgrade
|
Net Income | 1,400 | 940.56 | 411.52 | 111.35 | 229 | Upgrade
|
Net Income to Common | 1,400 | 940.56 | 411.52 | 111.35 | 229 | Upgrade
|
Net Income Growth | 48.88% | 128.56% | 269.58% | -51.38% | 150.58% | Upgrade
|
Shares Outstanding (Basic) | 2,223 | 2,239 | 1,960 | 1,856 | 2,000 | Upgrade
|
Shares Outstanding (Diluted) | 2,223 | 2,239 | 1,960 | 1,856 | 2,000 | Upgrade
|
Shares Change (YoY) | -0.75% | 14.28% | 5.59% | -7.21% | - | Upgrade
|
EPS (Basic) | 0.63 | 0.42 | 0.21 | 0.06 | 0.11 | Upgrade
|
EPS (Diluted) | 0.63 | 0.42 | 0.21 | 0.06 | 0.11 | Upgrade
|
EPS Growth | 50.00% | 100.00% | 250.00% | -45.45% | - | Upgrade
|
Free Cash Flow | 1,748 | 947.26 | 644.44 | 750.94 | 560.59 | Upgrade
|
Free Cash Flow Per Share | 0.79 | 0.42 | 0.33 | 0.41 | 0.28 | Upgrade
|
Dividend Per Share | 0.270 | 0.225 | 0.093 | - | - | Upgrade
|
Dividend Growth | 20.00% | 141.94% | - | - | - | Upgrade
|
Gross Margin | 36.09% | 30.69% | 24.37% | 18.41% | 17.59% | Upgrade
|
Operating Margin | 30.16% | 24.59% | 17.56% | 12.28% | 12.53% | Upgrade
|
Profit Margin | 24.32% | 19.50% | 10.77% | 3.45% | 6.28% | Upgrade
|
Free Cash Flow Margin | 30.36% | 19.64% | 16.87% | 23.23% | 15.36% | Upgrade
|
EBITDA | 2,278 | 1,730 | 1,217 | 919.79 | 948.73 | Upgrade
|
EBITDA Margin | 39.57% | 35.87% | 31.85% | 28.46% | 26.00% | Upgrade
|
D&A For EBITDA | 541.74 | 543.6 | 546.07 | 522.99 | 491.29 | Upgrade
|
EBIT | 1,737 | 1,186 | 670.77 | 396.8 | 457.44 | Upgrade
|
EBIT Margin | 30.16% | 24.59% | 17.56% | 12.28% | 12.53% | Upgrade
|
Effective Tax Rate | 16.40% | 15.85% | 15.61% | 16.96% | 17.05% | Upgrade
|
Revenue as Reported | 5,758 | 4,823 | 3,821 | 3,232 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.